NCT07093333View on ClinicalTrials.gov

A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Antibody-Associated Psychiatric Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

March 30, 2027

Conditions
Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE)Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric DiseaseAutoimmune Encephalitis
Interventions
DRUG

ART5803

A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.

All Listed Sponsors
lead

Arialys Australia Pty Ltd

INDUSTRY